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Abstract
The genus Enterovirus of the family Picornaviridae contains many important human patho-
gens (e.g., poliovirus, coxsackievirus, rhinovirus, and enterovirus 71) for which no antiviral
drugs are available. The viral RNA-dependent RNA polymerase is an attractive target for
antiviral therapy. Nucleoside-based inhibitors have broad-spectrum activity but often exhibit
off-target effects. Most non-nucleoside inhibitors (NNIs) target surface cavities, which are
structurally more flexible than the nucleotide-binding pocket, and hence have a more narrow
spectrum of activity and are more prone to resistance development. Here, we report a novel
NNI, GPC-N114 (2,2'-[(4-chloro-1,2-phenylene)bis(oxy)]bis(5-nitro-benzonitrile)) with
broad-spectrum activity against enteroviruses and cardioviruses (another genus in the pi-
cornavirus family). Surprisingly, coxsackievirus B3 (CVB3) and poliovirus displayed a high
genetic barrier to resistance against GPC-N114. By contrast, EMCV, a cardiovirus, rapidly
acquired resistance due to mutations in 3Dpol. In vitro polymerase activity assays showed
that GPC-N114 i) inhibited the elongation activity of recombinant CVB3 and EMCV 3Dpol,
(ii) had reduced activity against EMCV 3Dpol with the resistance mutations, and (iii) was
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most efficient in inhibiting 3Dpol when added before the RNA template-primer duplex. Eluci-
dation of a crystal structure of the inhibitor bound to CVB3 3Dpol confirmed the RNA-binding
channel as the target for GPC-N114. Docking studies of the compound into the crystal struc-
tures of the compound-resistant EMCV 3Dpol mutants suggested that the resistant pheno-
type is due to subtle changes that interfere with the binding of GPC-N114 but not of the
RNA template-primer. In conclusion, this study presents the first NNI that targets the RNA
template channel of the picornavirus polymerase and identifies a new pocket that can be
used for the design of broad-spectrum inhibitors. Moreover, this study provides important
new insight into the plasticity of picornavirus polymerases at the template binding site.
Author Summary
Virus replication relies on multiplication of viral genomes by viral polymerases. For en-
teroviruses, a large group of clinically important human pathogens for which no antiviral
therapy is available, this function is performed by 3Dpol, the RNA-dependent RNA poly-
merase. 3Dpol is therefore an attractive target for novel antiviral strategies. Most polymer-
ase inhibitors identified today are nucleoside analogs, a class of compounds that exert
broad-spectrum activity but often suffer from off-target effects. Non-nucleoside inhibitors
on the other hand, in general have a more narrow spectrum of activity and are more prone
to resistance development because in most cases they bind the surface of the enzyme
which is less conserved and structurally more flexible. In this study, we present the identi-
fication of GPC-N114 as a non-nucleoside inhibitor of 3Dpol with broad-spectrum antivi-
ral activity against both enteroviruses and cardioviruses, which also belong to the
picornavirus family. Remarkably, it acts by targeting the RNA template-primer binding
site in the core of 3Dpol, making GPC-N114 the first anti-picornaviral compound with this
mechanism of action. Thus, the characterization of GPC-N114 has led to the identification
of a novel drug-binding pocket in 3Dpol that can serve as a starting point for antiviral
drug design.
Introduction
The family Picornaviridae contains 12 genera, and includes many human and animal patho-
gens (reviewed in [1]). Among these is the genus Enterovirus which contains four human en-
terovirus species (HEV-A, -B, -C, -D), three human rhinovirus species (HRV-A, -B, -C),
simian enterovirus, bovine enterovirus, and porcine enterovirus. The HEV species include po-
liovirus (PV), coxsackievirus (CV), echovirus, and several numbered enteroviruses (EV). PV is
the cause of poliomyelitis, which can lead to acute flaccid paralysis. Enterovirus 71, a major
cause of hand-foot-and-mouth disease, is also frequently associated with flaccid paralysis and
is a growing concern due to major epidemics in Southeast Asia. Coxsackieviruses are the main
cause of viral meningitis, conjunctivitis, herpangina, myocarditis, and pancreatitis. HRV infec-
tions manifest themselves in most cases as the relatively mild common cold, but can cause seri-
ous exacerbations in patients with asthma or chronic obstructive pulmonary disease (COPD).
Other well-known picornavirus genera are Hepatovirus, which contains hepatitis A virus,
Aphthovirus, which contains foot-and-mouth disease virus (FMDV), and Cardiovirus, which
includes encephalomyocarditis virus (EMCV), Theiler's murine encephalomyelitis virus, and
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the recently discovered Saffold virus (SAFV), which, unlike the other cardioviruses, is a
human-tropic virus.
Currently, the toolbox to control picornavirus infections consists solely of vaccines against
PV, hepatitis A virus, and FMDV. Prevention of diseases caused by the non-polio enteroviruses
through vaccination seems unachievable given the great number of serotypes, with about 30
coxsackieviruses, 30 echoviruses, 50 numbered enteroviruses, and more than 150 rhinoviruses
[2]. With this in mind, current efforts are aimed at developing antiviral compounds with
broad-spectrum activity, targeting a wide range of viruses within a genus or ideally even multi-
ple genera. No specific antiviral drugs have yet been clinically approved for the treatment of en-
teroviruses or any other picornavirus.
Picornaviruses are non-enveloped RNA viruses with a single-stranded 7–8 kb RNA genome
of positive polarity. Upon entry, the viral RNA is translated into a polyprotein which is proteo-
lytically processed by viral proteases to release the structural proteins (VP1-4) and the non-
structural proteins (2A-2B-2C-3A-3B-3C-3Dpol and in some genera L) as well as some stable
precursors. The genome is replicated via a negative-sense RNA intermediate by 3Dpol, the viral
RNA-dependent RNA polymerase (RdRP). For this, 3Dpol uses the viral protein 3B, in this con-
text usually termed VPg (viral protein genome-linked), as a primer.
The structure of 3Dpol has been studied extensively in the past decades. Crystal structures
have been reported of 3Dpol of the enteroviruses CVB3, PV, EV71, HRV1B, HRV14, and
HRV16, and of the aphthovirus FMDV [3–10]. These enzymes adopt a classical right hand ar-
chitecture, with fingers, palm and thumb subdomains providing the correct geometrical ar-
rangement of substrate molecules and metal ions at the polymerase active site for catalysis [11].
In addition, in all picornavirus RdRPs, the conformation of the right hand is closed by the con-
nection of fingers and thumb sub-domains through the N-terminal portion of the protein and
several loops protruding from fingers, named the fingertips. This connection leads to the for-
mation of a completely encircled active site and largely restricts the inter-domain mobility.
Three well-defined channels have been identified in the RdRP structures that allow access to
the active site of the incoming rNTPs and the RNA template, as well as the exit path of the
newly synthesized dsRNA product [11]. Seven conserved structural elements, termed motifs
A–G, have been defined. Motifs A–E, located in the palm subdomain, are involved in nucleo-
tide and nucleic acid binding as well as catalysis. Motifs F and G, located in the fingers, play a
critical role in the binding of nucleoside triphosphates and RNA templates [12].
Given its critical role in genome replication, 3Dpol is regarded as an attractive target for anti-
viral drugs. Polymerase inhibitors can be subdivided into two classes. Most inhibitors identified
so far fall under the class of nucleoside/nucleotide analogs, which compete with endogenous
nucleotides and may act as chain terminators and/or mutagens. One example in this class is ri-
bavirin which induces lethal mutagenesis [13]. The second class of polymerase inhibitors are
the non-nucleoside inhibitors (NNI) which can have a variety of mechanisms of action, e.g.,
stabilizing the enzyme such that necessary conformational changes cannot take place [14]. Fre-
quently, these NNIs bind enzyme surfaces which are more variable between viruses and conse-
quently NNIs are more likely to have a restricted spectrum of activity. Also, the barrier to
resistance is lower due to the greater tolerance to amino acid substitutions. A few NNIs active
against picornaviruses have been discovered, but for most of them, the mechanism of action re-
mains poorly characterized [15–22]. In this study, we report a novel NNI, GPC-N114 that, un-
like most NNIs, binds the core of 3Dpol and possesses broad-spectrum activity against
enteroviruses and cardioviruses. GPC-N114 represents the first picornavirus 3Dpol inhibitor
that targets the template-binding site and reveals a novel pocket in 3Dpol that is amenable for
broad-spectrum inhibition.
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Results
GPC-N114 is an inhibitor of enterovirus and cardiovirus replication
We recently described a series of 5-nitro-2-phenoxybenzonitriles that inhibit in vitro enterovi-
rus replication [23]. Further optimization of this class of molecules led to the identification of
2,2'-[(4-chloro-1,2-phenylene)bis(oxy)]bis(5-nitro-benzonitrile), hereafter referred to as GPC-
N114 (Fig. 1A), with potent and selective in vitro antiviral activity against CVB3. This small
molecule inhibits CVB3 replication in multicycle CPE-reduction antiviral assay with a 50% ef-
fective concentration (EC50) of 0.15 ± 0.02 μM (Table 1).
To study its spectrum of activity, GPC-N114 was evaluated in similar multicycle antiviral
assays with representatives of the different HEV and HRV species, as well as several other pi-
cornaviruses. All enteroviruses and rhinoviruses included in this study were found to be sensi-
tive to the inhibitory effect of GPC-N114, with EC50 values ranging from 0.1 μM to 1.7 μM
(Fig. 1B and Table 1). GPC-N114 also inhibited the replication of EMCV (strain mengovirus),
a member of the genus Cardiovirus (EC50 = 5.4 ± 0.49 μM). By contrast, FMDV and equine rhi-
nitis A virus (ERAV), two members of the genus Aphthovirus, proved insensitive to its inhibi-
tory effect (tested with concentrations up to 25 μM and 100 μM, respectively).
To evaluate the antiviral effect of GPC-N114 in a single round of replication, CVB3 and
EMCV, as representatives of the enterovirus and cardiovirus genus, were incubated in the pres-
ence of different concentrations of the compound and virus titers were determined at 8 h post
infection (p.i.). Cell viability assays performed in parallel showed that GPC-N114 was not toxic
at these concentrations (S1A Fig.). For CVB3, the maximal inhibitory effect was obtained with
concentrations of 3 μM and higher, although replication was not fully abrogated (Fig. 1C).
Replication of EMCV was fully inhibited at concentrations of 10 μM or higher (Fig. 1C).
Therefore, a concentration of 10 μMwas selected for all further cellular assays. Detailed analy-
sis of the kinetics of CVB3 and EMCV replication at this concentration showed that GPC-
N114 strongly delayed virus replication (Fig. 1D and S1B Fig.). Comparable results were ob-
served for a panel of other enteroviruses (EV71, CVA21, HRV2, and HRV14) and cardio-
viruses (EMCV and SAFV) (Fig. 1E and S1B Fig.). Again, no antiviral activity was observed
against the aphthovirus ERAV (Fig. 1E).
Together, these results demonstrate that GPC-N114 exerts broad-spectrum in vitro antiviral
activity, inhibiting the replication of a representative panel of viruses belonging to the enterovi-
rus and cardiovirus genera from the picornavirus family.
GPC-N114 targets the RNA replication stage of the virus replication
cycle
To identify the stage of the replication cycle that is targeted by GPC-N114, we used CVB3 and
EMCV subgenomic replicons in which (a part of) the P1 coding region has been replaced with
the firefly luciferase gene. Luciferase expression thus allows the quantification of translation
and replication of the viral RNA. At 2 h post-transfection, a time point when no viral RNA rep-
lication has taken place yet [24], luciferase production from both replicons due to translation
of incoming RNA was comparable in the presence and absence of GPC-N114 (Fig. 1F), sug-
gesting that GPC-N114 does not affect translation. However, at later time points, luciferase lev-
els were lower in GPC-N114-treated cells in comparison with mock-treated control cells for
both the CVB3 and the EMCV replicon. In agreement with the single cycle assays, the EMCV
replicon proved more sensitive to the inhibitory effect of GPC-N114 than the CVB3 replicon.
These results indicate that GPC-N114 targets the viral RNA replication stage.
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Fig 1. GPC-N114 inhibits picornavirus replication. (A) Structural formula of GPC-N114. (B)
Representative dose-response curves of multicycle CPE-reduction assays for CVB3, PV1, and EV71. CPE
was quantified by MTS assay at 3 d p.i. and is expressed as percentage of uninfected, untreated controls. (C,
D) Antiviral activity of GPC-N114 against CVB3 and EMCV. BGM cells were infected with CVB3 (left panels)
or EMCV (right panels) at an MOI of 0.1. Immediately after infection, GPC-N114 was added at the indicated
concentrations (C) or at 10 μM (D). The enterovirus inhibitor guanidine hydrochloride (GuHCl) and the
cardiovirus inhibitor dipyridamole were included as controls. Virus titers were determined by endpoint titration
after 8 h (C) or at the indicated times p.i. (D). Experiments were performed in triplicate and mean values ± SD
are depicted. (E) Antiviral activity of GPC-N114 against a range of picornaviruses. Cells were infected with
the indicated viruses at an MOI of 0.5 after which 10 μMGPC-N114 was added. Virus titers were determined
A Novel Non-nucleoside Inhibitor of Picornavirus Polymerases
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To determine whether the impaired replication in the presence of GPC-N114 is caused by a
defect in the processing of the viral polyprotein, the viral proteins were visualized by metabolic
labeling. CVB3-infected BGM cells were pulse-labeled with [35S]Met in the presence or absence
of the compound between 5.5 and 6 h p.i., a time when translation of cellular, capped mRNAs
is shut off by the virus [25]. The labeled proteins were analyzed by SDS-PAGE and autoradi-
ography. The quantity and pattern of the viral proteins was similar for treated and untreated
samples (S2 Fig.), demonstrating that GPC-N114 does not affect synthesis or processing of the
viral polyprotein.
EMCV variants resistant to GPC-N114 carry mutations in 3Dpol
By serial passaging of virus in the presence of increasing concentrations of GPC-N114, we
aimed to select for GPC-N114-resistant virus. For this, we used a protocol that previously al-
lowed us to select virus variants resistant against a variety of compounds on different cell lines
[26–28]. However, despite 32 passages on Vero cells and several attempts, no compound-resis-
tant CVB3 isolates were obtained, indicating a high resistance barrier for this virus to GPC-
at 8 h p.i. Experiments were performed in triplicate and mean values ± SD are depicted. (F) GPC-N114
inhibits viral RNA replication. RNA of subgenomic replicons of CVB3 or EMCV was transfected into BGM
cells. Subsequently, cells were treated either with 0.1% DMSO, 10 μMGPC-N114, 2 mMGuHCl, or 80 μM
dipyridamole. Firefly luciferase levels were determined 2, 4, 6, and 8 h after RNA transfection to assess the
level of replication and translation. Experiments were performed in triplicate and mean values ± SD
are depicted.
doi:10.1371/journal.ppat.1004733.g001
Table 1. Antiviral activity of GPC-N114.
Serotype Species Cell line EC50 (μM)
Enterovirus
EV71 HEV-A RD 0.13 ± 0.05
CVA16 HEV-A Hela H 0.21 ± 0.02
CVB3 HEV-B Vero 0.15 ± 0.02
E11 HEV-B BGM 0.93 ± 0.01
CVA21 HEV-C Hela R19 0.94 ± 0.23
PV1 HEV-C BGM 1.00 ± 0.60
PV2 HEV-C BGM 0.88 ± 0.32
PV3 HEV-C BGM 0.26 ± 0.01
EV68 HEV-D Hela R19 1.44 ± 0.13
EV70 HEV-D Hela R19 1.55 ± 0.28
HRV2 HRV-A Hela R19 0.55 ± 0.03
HRV14 HRV-B Hela R19 1.73 ± 0.25
Cardiovirus
Mengovirus EMCV BGM 5.44 ± 0.49
Aphthovirus
FMDV-O FMDV BHK-21 >25
FMDV-A FMDV BHK-21 >25
ERAV-1 ERAV BGM >100
Shown are mean values calculated from at least three experiments ± SD. The cytotoxicity values (CC50)
were for Hela H cells 8.54 ± 0.42 μM, for Hela R19 cells 7.07 ± 0.38 μM, and for RD, BGM, and Vero cells
>100 μM
doi:10.1371/journal.ppat.1004733.t001
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N114. Also no resistant viruses were isolated on BGM cells. The possibility that the inability to
obtain resistant CVB3 was due to the incomplete inhibition of replication by GPC-N114 (as in-
dicated by single-cycle assays, though CPE was completely inhibited in multicycle assays), re-
sulting in a too low selection pressure, seems unlikely because we also failed to isolate GPC-
N114-resistant variants of PV1 (of which replication was completely blocked by GPC-N114 in
a single-cycle assay, S3 Fig.) and E9. In contrast, three independent virus pools of EMCV
showed phenotypic resistance after as few as three or four serial passages in the presence of
suboptimal concentrations of the compound. Viral RNA was isolated from these virus pools
and the regions coding for the non-structural proteins were sequenced. Interestingly, the three
virus pools each contained a single missense mutation compared to wild-type (wt) virus. These
mutations were located either at nucleotide 7115 (A7115G) or 7127 (A7127G) resulting in
amino acid changes M300V and I304V in the viral RdRP, 3Dpol, respectively (Fig. 2A).
To verify the causal relationship between these mutations and the resistance phenotype, the
mutations were introduced into the EMCV cDNA clone pM16.1 and mutant viruses were gen-
erated. In the multicycle CPE-reduction assay, the EC50 dramatically increased from 5.44 ±
0.49 μM for EMCV wt to>100 μM for EMCV 3D-M300V and 3D-I304V, indicating that the
mutants were resistant to the compound (Fig. 2A and B). Accordingly, while the production
of infectious virus particles by wt virus was strongly inhibited in a single cycle assay, virus titers
of the mutant viruses after 8 h were unaffected by the presence of 10 μMGPC-N114 (Fig. 2C).
As expected, the mutations did not confer resistance to the cardiovirus inhibitor dipyridamole.
These results demonstrate that the mutations in 3Dpol were indeed responsible for the resis-
tance phenotype of the isolated virus pools.
The X-ray structure of EMCV 3Dpol has been recently reported [29]. It shows that the
amino acids M300 and I304 are both located in structural motif B both on the same face of
Fig 2. Mutations in EMCV 3Dpol confer resistance to GPC-N114. (A) Location of the mutations in GPC-N114-resistant EMCV pools and the EC50 of
recombinant viruses as determined in a multicycle CPE-reduction assay. (B,C) Recombinant EMCV 3Dpol mutants are resistant to GPC-N114, as shown by
multicycle CPE reduction assay (B) or single cycle growth curves (C). For technical details, see legend to Fig. 1. (D) Ribbon diagram of the three-dimensional
structure of EMCV 3Dpol shown in the conventional orientation, as if looking into a right hand. The two residues mutated in GPC-N114-resistant EMCV (M300
and I304) are indicated in magenta. (E) GPC-N114 inhibits EMCV 3Dpol activity, but not by competing with UTP. Polymerase elongation activity in the
presence of a range of concentrations of GPC-N114 was determined by measuring incorporation of [3H]UTP using poly(rA)/dT15 as template-primer.
Michaelis-Menten plots of the initial velocity of EMCV 3Dpol elongation activity determined at different concentrations of UTP and GPC-N114 are depicted.
The curves shown are based on a non-competitive mode of inhibition. (F) Inhibition constants of GPC-N114 on EMCV 3Dpol wt and mutants M300V and
I304V. Inhibition constants (Ki) were calculated from at least three experiments performed as in (E) and values shown are mean ± SD. Statistical analysis
was performed with unpaired Student’s t-test.
doi:10.1371/journal.ppat.1004733.g002
A Novel Non-nucleoside Inhibitor of Picornavirus Polymerases
PLOS Pathogens | DOI:10.1371/journal.ppat.1004733 March 23, 2015 7 / 23
helix α10 (which is part of the palm subdomain of the polymerase), close to the active site
(Fig. 2D). Both residues are buried in the core of the protein and their side chains are involved
in hydrophobic interactions that stabilize the local structure.
Having identified GPC-N114 resistance mutations in EMCV 3Dpol, we set out to test wheth-
er the corresponding mutations in CVB3 (i.e., 3D-I296V and 3D-M300V) would yield GPC-
N114-resistant variants. Mutations were introduced in a CVB3 cDNA by site-directed muta-
genesis and viruses were obtained by transfection of run-off transcripts in cells. The mutant vi-
ruses displayed similar increases in virus titer after 8 hours as CVB3 wt in the absence of
compound, but did not show a compound-resistant phenotype (S4A Fig.). Also mutation
S299T in CVB3 3Dpol, which was previously shown to provide resistance against the 3Dpol in-
hibitor amiloride [19,22], failed to confer resistance to GPC-N114 (S4B Fig.).
GPC-N114 inhibits in vitro polymerase activity
The location of the EMCV resistance mutations suggested that GPC-N114 targets the activity
of 3Dpol. To verify this, biochemical assays were performed using purified EMCV 3Dpol in the
presence or absence of GPC-N114. Briefly, elongation of a dT15 primer on a poly(rA) template
by recombinant enzyme was determined by measurement of the rate of incorporation of [3H]
UTP. Elongation activity of EMCV 3Dpol on the poly(rA) template was inhibited by GPC-
N114 in a dose-dependent manner (Fig. 2E), which is in line with the resistance to the com-
pound mapping to 3Dpol in EMCV. Using the same template-primer and metal ion (i.e.,
Mg2+), GPC-N114 did not affect the elongation activity of the polymerase domain of the den-
gue virus (DENV) NS5 RdRP (S5 Fig., IC50> 100 μM), demonstrating that the inhibition
of EMCV 3Dpol activity was not due to an unspecific interference with these components of
the assay.
An inhibition constant (Ki) of 1.3 μMwas calculated from the EMCV 3Dpol elongation ac-
tivity measured at multiple UTP and inhibitor concentrations (Fig. 2F). Fig. 2E shows repre-
sentative Michaelis-Menten plots of the results acquired with EMCV 3Dpol. The data were
fitted by non-linear regression assuming a competitive, noncompetitive, uncompetitive or
mixed mode of inhibition. The model of noncompetitive inhibition provided the best fit, with
the maximum velocity (Vmax) of the reaction declining with increasing concentrations of the
compound. This indicates a noncompetitive mode of inhibition with respect to UTP (and pre-
sumably NTPs in general). Markedly higher inhibition constants were observed for the two
resistant mutants (M300V, 26.9 μM; I304V, 10.3 μM) as compared to that for the wt enzyme
(1.3 μM) (Fig. 2F). Thus, GPC-N114 inhibited EMCV 3Dpol elongation activity, which could
be counteracted by mutations M300V and I304V.
GPC-N114 binds 3Dpol at the site of the template acceptor nucleotide
Co-crystallization of 3Dpol in complex with GPC-N114 was attempted to study the binding of
the compound to picornavirus polymerases. Co-crystals of EMCV 3Dpol with the inhibitor
were not obtained, but the structure of the complex of CVB3 3Dpol with GPC-N114 was ob-
tained by X-ray crystallography at 2.9 Å resolution (Table 2). The analysis of the difference
electron density maps revealed the presence of extra densities to position the inhibitor within a
pocket located at the bottom of the template channel, mimicking the position of the template
acceptor nucleotide, the nucleotide which will base-pair with the incoming nucleotide
(Fig. 3A-C and S6 Fig.). The GPC-N114-binding pocket is in close proximity to the location
of the mutated residues in resistant EMCV 3Dpol (compare Fig. 2D and Fig. 3A). The com-
pound bound in a conformation that perfectly fitted the shape of the pocket formed by residues
L107, E108, L110, D111, T114 of motif G, R188, Y195, H199 of motif F, T294, S295, I296 of
A Novel Non-nucleoside Inhibitor of Picornavirus Polymerases
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motif B and Y327 of motif A (Fig. 3A and 3B). Most of these residues are conserved in picor-
naviral polymerases (S7 Fig.). Among all contacts observed, the stacking interaction between
Y195 and the central chlorophenyl ring of GPC-N114 appeared to be an important determi-
nant of binding. This tyrosine is strictly conserved in enterovirus polymerases but not con-
served in FMDV and EMCV. The first 2-cyano-4-nitrophenyl ring was oriented towards the
entrance of the template channel, interacting with residues of motif G and B of CVB3 3Dpol,
whereas the second 2-cyano-4-nitrophenyl ring appeared partially exposed to the solvent, oc-
cupying the position expected for the template acceptor base (Fig. 3C). The interacting resi-
dues appear to be in direct contact with the RNA templates in all picornaviral 3Dpol–RNA
complexes determined so far [4,12,30,31]. Structural comparisons between unbound and GPC-
N114-bound CVB3 3Dpol revealed that the polymerase did not undergo any major conforma-
tional change upon binding of the compound. This preservation of the template cavity confor-
mation extended to the interacting side chains, which maintained their native conformation
upon GPC-N114 binding.
Table 2. Data collection and reﬁnement statistics.
Data collection CVB3 3Dpol–GPC-N114 CVB3 3Dpol–GPC-N143 EMCV 3Dpol-M300V EMCV 3Dpol-I304V
Space Group P43212 P43212 I4122 C2
Cell dimensions
a, b, c (Å) 74.74, 74.74, 289.1 74.62, 74.62, 288.43 122.6, 122.6, 194.5 232.3, 140.8, 171.8
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 126, 90
Rmerge 8.1 7.2 8.1 13.7
I/σI 7.6 9.2 9.0 5.2
Completeness (%) 99.8 96.8 94.5 99.5
Multiplicity 3.6 3.6 2.8 2.9
Reﬁnement
Resolution (Å) 72.4–2.9 72.2–2.7 43.3–2.2 49.4–3.2
No. reﬂections (unique) 18099 21638 34387 69711
Rwork† / Rfree‡ 21.1/ 22.9 20/24 22/26 21/25
No. Atoms
- Protein 3746 3765 3711 22088
- Ligand 31 31 0 0
- GOL + ions 49 49 24 61
- Water 81 49 176 72
B-factors (Å2)
- Protein 69.39 48.47 31.3 78.9
- Water + Ligands 65.51 59.69 47.3 59.55
R.m.s. deviations
- Bond lengths (Å) 0.011 0.019 0.0042 0.0049
- Bond angles (°) 1.319 1.79 0.879 0.912
Ramachandran plot
- Residues in preferred regions 370 (89.8%) 431 (83.49%) 450 (98.3%) 2586 (94.1%)
- Residues in allowed regions 42 (10.2%) 30 (6.51%) 8 (1.7%) 154 (5.6%)
† Rwork = ∑hkl ||Fobs(hkl)|—|Fcalc(hkl)|| / ∑hkl |Fobs(hkl)|, where Fobs and Fcalc are the structure factors, deduced from measured intensities and
calculated from the model, respectively.
‡ Rfree = as for Rwork but for 5% of the total reﬂections chosen at random and omitted from reﬁnement.
doi:10.1371/journal.ppat.1004733.t002
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We also solved the X-ray structure of the complex of CVB3 3Dpol with a second inhibitor of
the GPC series, GPC-N143, at 2.7 Å resolution (S8A Fig. and Table 2). This compound con-
tains a central fluorophenyl ring instead of a chlorophenyl ring and displays similar antiviral
activity as GPC-N114 (S8A and S8B Fig.). As expected, the GPC-N143 binding site is identical
to that of GPC-N114, establishing almost equivalent interactions (Fig. 3B, S6 Fig. and S8D
Fig.). Thus, the crystallographic data demonstrate that GPC-N114 and GPC-N143 specifically
interact with CVB3 3Dpol at the template channel without having major effects on the structure
of the enzyme.
Model of EMCV 3Dpol–GPC-N114 interactions and the structure of
M300V and I304V mutants
All attempts to obtain the structure of EMCV 3Dpol–GPC-N114 complex were unsuccessful,
however, the superposition of the CVB3 3Dpol–GPC-N114 complex onto the unbound EMCV
3Dpol structures allowed us to define the putative inhibitor binding site in the EMCV enzyme
(Fig. 4A). The overall shape of this site is similar in the two enzymes, but some important con-
tacts are lost in EMCV (e.g., the stacking interaction between the side chain Y195 and the
Fig 3. The binding site of GPC-N114 on CVB3 3Dpol. (A) Ribbon diagram of the CVB3 3Dpol structure
(green). The inhibitor bound to the bottom of the template channel is shown in stick representation in yellow.
(B) Interaction network between GPC-N114 and its binding pocket of CVB3 3Dpol represented by surfaces.
The polymerase residues in direct contact with the inhibitor are shown with carbon atoms in green and
explicitly labeled. Hydrogen bonds are depicted as dashed lines. (C) Top down cross-sectional view of the
molecular surface of CVB3 3Dpol with the electrostatic potential, represented in blue and red for positive and
negative charges, respectively. The trajectory of the RNA template (green) is compared with the position of
the GPC-N114 inhibitor (yellow). The inset box shows a close up of the position of the inhibitor that is
coincident with that of the template acceptor nucleotide. The predicted position of the RNA template was
determined using the FMDV 3Dpol–RNA complex (PDB entry 1WNE) as a guide.
doi:10.1371/journal.ppat.1004733.g003
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central ring of GPC-N114 is absent due to the substitution of this residue by alanine in
EMCV). The model also shows that the major polymerase–inhibitor interactions are mediated
by residues of the motif B loop (β10-α10) (Fig. 4A and S7 Fig.). The resistance mutations at
EMCV 3Dpol residues 300 and 304 of helix α10 are close to the putative GPC-N114 binding
site. However, only the long lateral chain of the EMCV wt residue M300 is able to establish a
direct contact with the compound.
The apo structures of the EMCVM300V and I304V polymerase mutants were obtained
using the same crystallization conditions as for the wt enzyme [29], yielding two different types
of crystals for the mutants. The M300V mutant crystallized in the space group I4122 form with
one 3Dpol molecule in the asymmetric unit (a.u.) and diffracted to 2.2 Å resolution. The 3Dpol
I304V mutant crystallized in the space group C2 with six polymerase molecules per a.u. and
diffracted to 3.2 Å resolution. Data collection and refinement statistics are summarized in
Table 2. Structural comparisons showed that the mutant polymerases were almost identical to
the wt enzyme. The main differences were concentrated in helix α10, which contains the mu-
tated residues, and in the preceding loop B. The side chains of residues 300 and 304 participate
in a large hydrophobic cluster linking α10 with helices α2 (Y75), α6 (F194, A195, F199), α7
(I210) and α8 (L241, F255 and F256), included in the inner fingers. The substitutions of the
methionine and isoleucine side chains by the shorter valine in the mutants imply a weakening
of these hydrophobic interactions. This could result in an increased flexibility of α10, including
the disruption of the last helical turn, and of the B-loop, which appears to have a key role in
GPC-N114 binding in EMCV 3Dpol (Fig. 4). In addition, the substitution with valine may dis-
rupt the interaction of residue 300 with the compound.
GPC-N114 has a stronger inhibitory effect when added to 3Dpol before
the RNA template-primer duplex
Prompted by the identification of the binding site of GPC-N114 on CVB3 3Dpol, we analyzed
the effects of GPC-N114 on CVB3 3Dpol in more detail. Consistent with the data obtained for
EMCV 3Dpol, GPC-N114 inhibited CVB3 3Dpol elongation activity of the homopolymeric sub-
strate poly(rA)/dT15 (Fig. 5A). Again inhibition was noncompetitive with respect to UTP.
Since the binding sites of GPC-N114 and the template on CVB3 3Dpol overlapped, we aimed to
explore whether GPC-N114 competes with the RNA template-primer duplex for binding to
Fig 4. Effects of mutations M300V and I304V on the GPC-N114 binding site in EMCV 3Dpol. (A) Surface representation of the putative GPC-N114
binding pocket in EMCV 3Dpol (slate blue) with the modeled inhibitor depicted in atom color (carbon atoms in yellow). (B-D) Environment of 300 and 304
residues on EMCVwt and mutants 3Dpol. Motifs A and C are represented in transparent grey and motif B in solid color: (B) grey (wt), (C) cyan (M300V) and
(D) red (I304V). Residues interacting with motif B α-helix are shown as sticks colored by atom. The GPC-N114 binding site on CVB3 3Dpol is represented as
a yellow surface.
doi:10.1371/journal.ppat.1004733.g004
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3Dpol. A possible method to test whether GPC-N114 precludes binding of the enzyme to RNA
is by monitoring changes in fluorescence polarization signal [32] of a labeled symmetric het-
eropolymeric template-primer duplex (sym/sub-U) [33]. However, though GPC-N114 had an
inhibitory effect in the elongation assays with the homopolymeric poly(rA)/dT15 template-
primer (Fig. 5A), the compound failed to inhibit the incorporation of NTPs using the sym/
sub-U template-primer, the latter being in contrast with what we observed in the elongation
assays with the homopolymeric poly(rA)/dT15 template-primer (S9 Fig.). Therefore, an order-
of addition assay was performed to compare the efficiency of GPC-N114 when added to the
reaction mixture with 3Dpol before or after addition of poly(rA)/dT15. If GPC-N114 would af-
fect productive binding of the template-primer to 3Dpol, the inhibitor should display an im-
proved potency when added to the reaction mix with 3Dpol before the template-primer as
compared to after. When enzyme was pre-incubated with the inhibitor before adding the tem-
plate-primer on average a 3-fold (n = 3) reduction in the Vmax was observed (Fig. 5B), which
is consistent with the reported inactivation of picornavirus polymerases when they are incubat-
ed in the absence of nucleic acid [34]. Importantly, the IC50 value for GPC-N114 on CVB3
3Dpol was dramatically reduced (on average 14-fold, n = 3) when the compound was added to
the reaction mix before the template-primer (Fig. 5B). Unfortunately, this assay is not able to
discriminate between direct competition and the formation of a nonproductive ternary com-
plex consisting of GPC-N114–template-primer–3Dpol. Nevertheless, the observation that
GPC-N114 has a stronger inhibitory effect on 3Dpol activity when added before the template-
primer is compatible with the overlapping binding sites of the compound and the template-
primer on 3Dpol.
Fig 5. Characterization of the inhibitory mechanism of GPC-N114 on CVB3 3Dpol. (A) GPC-N114 does
not compete with UTP. The experiment was performed for CVB3 3Dpol as described in Fig. 2E for EMCV
3Dpol. (B) GPC-N114 is more efficient when added to the reaction mix before the template-primer. Order-of-
addition experiments were performed by measuring CVB3 3Dpol elongation activity when GPC-N114 was
added to the reaction mix before or after poly(rA)/dT15. A typical of three independent experiments
is presented.
doi:10.1371/journal.ppat.1004733.g005
A Novel Non-nucleoside Inhibitor of Picornavirus Polymerases
PLOS Pathogens | DOI:10.1371/journal.ppat.1004733 March 23, 2015 12 / 23
Discussion
There is a great need for broad-range antiviral compounds to treat infections with enterovi-
ruses, which includes important human pathogens such as poliovirus, coxsackievirus, enterovi-
rus 71, and rhinovirus. Here, we report a novel small molecule, GPC-N114 that exerts broad-
spectrum anti-enterovirus activity and also inhibits members of the genus Cardiovirus, such as
EMCV. Analysis of its mechanism of action revealed that GPC-N114 inhibits virus replication
at the stage of RNA replication. GPC-N114-resistant enterovirus variants could not be ob-
tained, but compound-resistant EMCV variants were readily selected in the presence of subop-
timal concentration of GPC-N114. These variants were found to carry mutations in the viral
RdRP, 3Dpol. Consistently, the in vitro elongation activity of CVB3 and EMCV 3Dpol was in-
hibited by GPC-N114, and the mutations identified in compound-resistant EMCV 3Dpol ren-
dered this polymerase less susceptible to inhibition. GPC-N114 did not compete with
incoming NTPs, but interfered with productive binding of the template-primer to 3Dpol in a
primer elongation assay. This is in agreement with the crystallographic studies of the CVB3
3Dpol–GPC-N114 complex which revealed that the binding site of the compound is located at
the junction of the palm and the fingers domains, and overlaps partially with the binding site
of the template.
A high barrier to resistance is a desirable feature for antiviral compounds since drug resis-
tance represents a major problem in the treatment of viral infections. Notably, no GPC-N114-
resistant enteroviruses (CVB3, PV1, E9) were obtained after several attempts and a large num-
ber of serial passages of these viruses in the presence of suboptimal concentrations of the com-
pound. Attempts to generate compound-resistant CVB3 by introduction of the mutations that
correspond to those identified in GPC-N114-resistant EMCV (i.e., 3D-I296V and 3D-M300V
in CVB3), also did not result in a compound-resistant phenotype. The reason for the inability
of enteroviruses to develop resistance against GPC-N114 remains to be established. A possible
explanation is that mutations that would confer resistance to GPC-N114 also impair binding
of the template-primer, thereby preventing replication. Although the exact reason remains to
be determined, our data suggest that the compound-binding site in enterovirus 3Dpol lacks the
conformational plasticity for resistance to develop, in contrast to most allosteric binding sites
at the enzyme surface.
In contrast, EMCV 3Dpol is sufficiently plastic to allow for substitutions that result in com-
pound-resistance. The amino acid changes are conservative with all three amino acids having
similar properties. Based on the constructed model, only the long side chain of M300 (equiva-
lent to I296 in CVB3 3Dpol, see Fig. 3B), would be in direct contact with the compound. In
contrast, I304 seems to be located relatively far away of the GPC-N114 binding cavity. Both
M300 and I304 are part of conserved structural motif B, which not only binds the RNA tem-
plate in the active site but also participates in the mechanism of RNA translocation through
fine movements of a loop located at the N-terminus of the motif, the B-loop [30,35]. Structural
data from picornavirus polymerases [30,35] as well as other RdRPs [36] suggest that the B-loop
is highly dynamic and that its dynamics can be regulated by external effectors [37]. The struc-
tures of the EMCV 3Dpol M300V and I304V mutants suggest that these mutations increase the
flexibility of this loop, thereby affecting the binding site of GPC-N114 and probably losing a di-
rect interaction with the shorter V300 side chain whilst retaining the ability to interact with the
template-primer.
EMCV 3Dpol and CVB3 3Dpol display a high structural similarity, but there is a major differ-
ence in the main interactions of these polymerases with GPC-N114 that could possibly under-
lie the difference in resistance emergence. In CVB3 3Dpol, the main interaction with GPC-
N114 is mediated by Y195. EMCV 3Dpol, however, possesses an alanine at this position which
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forms a weaker interaction (S10 Fig.). Due to this weaker interaction, a flexibility increase in
the compound-binding area induced by the B loop resistance mutations may result in a de-
creased binding of GPC-N114 to EMCV 3Dpol. For CVB3 3Dpol, a possible increase in flexibili-
ty induced by B loop mutations may not, or to a lesser extent, affect the binding of GPC-N114
due to its strong interaction with Y195.
GPC-N114 proved to be not a very robust compound in biochemical assays, for which the
reason might be that it interferes with the binding of a by far larger molecule, the RNA tem-
plate-primer. Thus, despite our efforts, it remains to be established whether GPC-N114 inhibits
3Dpol elongation activity by competing with the template-primer for binding to 3Dpol or
whether binding of the compound results in the formation of an unproductive conformation
of the polymerase-template complex. Nevertheless, both the crystallographic studies as well as
the order-of-addition experiment strongly suggest that GPC-N114 affects binding of the tem-
plate-primer by 3Dpol. Compounds that interfere with binding of the template-primer have
been described for polymerases of some viruses, including DENV and HIV [38,39], but not for
any of the picornaviruses. The only known picornavirus polymerase inhibitors with a related
mechanism of action are two compounds that target the incoming NTP binding site in the PV
polymerase [15]. Clearly, the NTP binding site is close to, but distinct from, the GPC-N114
binding site. Hence, GPC-N114 is the first reported picornavirus polymerase inhibitor that
binds the site of the template acceptor nucleotide.
Polymerase inhibitors have demonstrated their importance for the treatment of other viral
infections such as those caused by HIV, herpesvirus, HBV and HCV. Unfortunately, it was not
possible to evaluate the antiviral effect of GPC-N114 in an animal model, since—despite exten-
sive attempts—we have not been able to formulate GPC-N114 (or GPC-N143) for administra-
tion. Notwithstanding this, the identification of a new druggable pocket in the polymerase
through the characterization of the mechanism of action of GPC-N114 may be key in the (in
silico) design of novel picornavirus polymerase NNIs.
Materials and Methods
Cells and reagents
Buffalo green monkey (BGM) kidney cells, HeLa R19 cells (obtained from G. Belov, University
of Maryland and Virginia-Maryland Regional College of Veterinary Medicine, US), baby ham-
ster kidney 21 (BHK-21) cells, and human rhabdomyosarcoma RD cells were grown at 37°C,
5% CO2 in Dulbecco’s Modified Eagle medium (DMEM) (Gibco) supplemented with 10% fetal
bovine serum and antibiotics [28,40]. The Hela H cells, BGM cells, and Vero cells used for the
multicycle CPE-reduction assays were maintained in Minimal Essential Medium supple-
mented with 10% FBS, 1% bicarbonate, and 1% L-glutamine [28].
The synthesis of GPC-N114 will be published elsewhere. Guanidine hydrochloride (GuHCl)
and dipyridamole were purchased from Sigma Aldrich. Dipyridamole was dissolved in ethanol
and GuHCl in water. The other compounds were dissolved in DMSO. GPC-N114 was used in
a concentration of 10 μM unless stated otherwise.
Viruses and infections
Coxsackievirus B3 (strain Nancy) was obtained by transfection of RNA transcripts of the full-
length infectious clone p53CB3/T7 linearized with SalI into BGM cells [41]. EMCV, strain
mengovirus, was obtained in a similar manner by transfection of RNA derived from cDNA
clone pM16.1 into BHK-21 cells [42]. EV68, EV70, EV71 (BrCr), E11 (Gregory), CVA16 (G-
10) and CVA21 (Coe) were obtained from the National Institute for Public Health and Envi-
ronment (RIVM, the Netherlands). Poliovirus 1–3 Sabin reference strains were obtained from
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dr. J Martin (NIBSC, UK). Human rhinoviruses 2 and 14 were supplied by Joachim Seipelt
(Medical University of Vienna, Austria). ERAV (NM11/67) was a gift from David Rowlands
and Toby Tuthill (University of Leeds, UK). Saffold virus (type 3) was described previously
[43]. The FMDV strains O1 Manisa and A22 Iraq 24/64 were used [44].
For virus infections, virus was added to subconfluent cell layers and allowed to adsorb for
30 minutes, after which virus was removed and fresh (drug-containing) medium was added to
the cells. At the indicated times p.i. the cells were freeze-thawed three times to release intracel-
lular virus particles. Virus titers were determined by endpoint titration according to the meth-
od of Reed and Muench and expressed as 50% cell culture infective doses (CCID50)/ml [45].
Multicycle CPE-reduction assays
The antiviral activity of compounds was determined as published previously [11,44]. In short,
the medium was removed from cells grown in 96-well plates and a serial dilution of compound
in medium with 2% FCS was added after which the cells were infected with virus at the lowest
MOI sufficient for full CPE development in infected, untreated cultures after three days of in-
cubation at 37°C. To quantify the level of CPE by MTS assay, the medium was then replaced
with AQueous One Solution Cell Proliferation Reagent (Promega) diluted in medium and incu-
bated at 37°C for 1–2 h. Subsequently, absorbance at 498 nm was measured. The measured val-
ues were used to calculate the cell viability ranging from 0% (full CPE with infected, untreated
cultures) to 100% (uninfected, untreated cultures). The 50% effective concentration (EC50)
was defined as the concentration of compound that resulted in a 50% reduction in virus-in-
duced CPE and was calculated using logarithmic interpolation.
Subgenomic replicon assay
The subgenomic replicons of CVB3 (pRib-LUC-CB3/T7) and EMCV (pEMCV-FLuc) encode
the cDNA clones of the corresponding virus except that the P1 area encoding the capsid pro-
teins has been (partially) replaced by the code for firefly luciferase [24,46]. The plasmids were
linearized with MluI or BamHI, respectively. RNA transcribed from the linearized plasmids
was used to transfect BGM cells plated in 24-well plates using the DEAE-dextran method as de-
scribed previously [24]. After transfection, cells were treated with DMSO or compound and in-
cubated at 37°C. At 2, 4, 6, and 8 h post-transfection, cells were washed with PBS, lysed and
luciferase levels were determined with the Luciferase Assay System (Promega) according to the
manufacturer’s instructions.
A similar procedure was followed for the PV1 subgenomic replicon assay pXpA-RenR-PV
except that luciferase activity was measured with the Renilla Luciferase Assay System (Pro-
mega), since this construct encodes the Renilla luciferase [47].
Metabolic labeling
For metabolic labeling of proteins, BGM cells were grown in 24-well plates to subconfluence
and infected with CVB3 at an MOI of 50. At 5 h post-infection, the medium was replaced with
300 μl of methionine-free medium for 30 min. Subsequently, the cultures were pulse-labeled in
methionine-free medium supplemented with [35S]Met in the absence or presence of 50 μM
GPC-N114 for 30 min. At 6 h post-infection, cells were lysed with lysis buffer [50 mM Tris
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.05% SDS]. Laemmli sample buffer
was added to the lysates, boiled for 5 min and analyzed on a 10% polyacrylamide gel containing
SDS. The gels were fixed in 30% methanol-10% acetic acid, rinsed in DMSO, fluorographed
with 20% 2,5-diphenyloxazole in DMSO, dried, and exposed to Kodak XAR film.
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Generation of GPC-N114-resistant virus
To obtain drug-resistant virus, three independent virus pools of CVB3 and EMCV were serially
passaged in the presence of a concentration series of GPC-N114 on subconfluent to confluent
Vero cultures in 96-well plates. The amount of virus used for infection was selected so that full
CPE was visible after 3 days of incubation in the absence of compound. The concentration se-
ries encompassed 8 different concentrations in 2-fold dilutions starting from 25–100 μM. After
3 to 4 days, the amount of CPE was assessed and supernatant collected from the culture with
the highest concentration of compound that still exhibited full CPE was used to perform the
next round of infection. This procedure was repeated 32 times (CVB3) or until there was a
clear increase in the concentration required for inhibition of CPE (EMCV) compared to wt
virus that was tested in parallel in each passage. Viral RNA was isolated from the resistant virus
pools using the GenElute Mammalian Total RNAMiniprep Kit (Sigma Aldrich) and used for
sequencing of the parts of the genome that encode the nonstructural proteins. The PCR prod-
uct containing the mutations found in the virus pools generated in this procedure was digested
with PinAI and NruI and cloned into pM16.1 to replace the corresponding wt sequence. The
resulting infectious clones pM16.1-3D-M300V and pM16.1-3D-I304V were sequenced to con-
firm the presence of the mutations.
The analogous mutations in CVB3 (I296V and M300V) were introduced into the infectious
cDNA p53CB3/T7CVB3 by site-directed mutagenesis. The mutant clones were sequenced to
confirm the presence of the mutations. The construction of pRibCB3/T7 with the S299T muta-
tion was described previously [48].
Recombinant EMCV and CVB3 was generated as described above and the presence of the
mutations was again confirmed by sequence analysis.
Protein expression and purification for biochemical activity assays
Recombinant CVB3 3Dpol and the RdRP domain of DENV NS5 (NS5-RdRP) were obtained as
previously described [49,50]. For expression and purification of EMCV 3Dpol, the coding se-
quence of 3Dpol (polyprotein domain from amino acid position 1834 to 2293) was amplified
on EMCV cDNAs (pM16.1 wt, 3D-M300V, and 3D-I304V) and cloned into pETG20A (kindly
provided by Dr. Arie Geerlof) by Gateway recombination (Life Technologies), downstream a
cleavable Hexahistidine-Thioredoxin tag using a two-step PCR protocol. The protein was ex-
pressed in E. coli Rosetta (DE3) pLysS strain (Novagen) at 17°C in Turbest Broth (Arcadia
Biotech). The purification of the protein and the tag removal were performed in non-denatur-
ing conditions as previously described [51]. The final size exclusion chromatography step was
performed in 10 mMHepes, 300 mM NaCl, 2mM dithiotreitol, pH 7.5.
Polymerase activity assays
The conditions for the polymerase elongation activity assays were adapted from conditions re-
ported previously [10,50]. EMCV 3Dpol filter-binding polymerase activity assays were con-
ducted in a mix of 50 μl containing 50 mMMOPS pH 7.0, 10 mM KCl, 4 mMMgCl2, 9%
glycerol, 2 μM dT15 (Invitrogen) annealed to 350 nM poly(rA) (GE Healthcare, average size
519 nt) (i.e., a molar ratio dT15:poly(rA) of 5.7:1), 1 μM EMCV 3Dpol, 50/100/200 or 500 μM
UTP and 2 μCi [3H]UTP (GE Healthcare, 35.5 Ci/mmol). The reaction mix excluding UTP
was incubated with either DMSO or GPC-N114 with a constant concentration of 5% DMSO
for 2 minutes after which the reaction was started by addition of labeled and unlabeled UTP.
Samples of 10 μl were taken after 0, 10, 20 and 30 min of incubation at 30°C and added to 50 μl
of 100 mM EDTA in 96-well sample plates to stop the reaction. Mixtures were then transferred
onto glass fiber filter mats with DEAE active groups (DEAE filtermat, Wallac) using a Filtermat
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Harvester (Packard Instruments). Filtermats were washed three times with 0.3 M ammonium
formate pH 8.0, twice with water, and once with ethanol after which they were dried and trans-
ferred into sample bags. Liquid scintillation fluid was added to the sample bags and incorpo-
ration of radiolabeled UTP was measured in counts per minute using a Wallac MicroBeta
TriLux Liquid Scintillation Counter.
For the DENV NS5 elongation assay the reaction mixture contained 50 mMHEPES pH 8.0,
10 mM KCl, 10 mMDTT, 5 mMMgCl2, 2 μM dT15 annealed to 350 nM poly(rA), 0.4 μM
DENV NS5-RdRP, 20 μMUTP and 2 μCi [3H]UTP. 10 μl samples were taken after 0, 30, 60,
and 90 minutes. Subsequently, the same procedure was followed as for EMCV 3Dpol.
The CVB3 3Dpol reaction mixture contained 50 mM Tris pH 7.0, 10 mM KCl, 0.8 mM
MgCl2, 9% glycerol, 2 μM dT15 annealed to 350 nM poly(rA), 20 nM CVB3 3D
pol, UTP (2, 5,
10 or 20 μM) and 0.5 μCi [3H]UTP. 10 μl samples were taken after 0, 5, 10, and 15 minutes.
For the order-of-addition experiment with CVB3 3Dpol, a reaction premix was assembled as
above but without poly(rA)/dT15, GPC-N114 and UTP. To this premix either a range of con-
centrations of GPC-N114 or 80 nM dT15 annealed to 14 nM poly(rA) were added. After an in-
cubation of 1 min at RT, the other component was added to the mix followed by an incubation
of several minutes at 30°C. The reaction was started by addition of UTP, and samples were
taken after 0, 3, 6, and 9 minutes.
The data were fitted using non-linear regression using Graphpad Prism 5.0.3. Ki values av-
eraged from at least three independent experiments were statistically compared between
EMCV 3Dpol wt and the 3Dpol mutants using a Student’s t-test.
Protein expression and purification for crystallography
Recombinant CVB3 3Dpol was over-expressed essentially as previously described [49], except
that the expression was carried out at 20°C. Stored pellets were resuspended in a cold lysis buff-
er containing 50 mM Tris HCl pH 9.0, 500 mMNaCl, 10 mM imidazole, 0.1% (v/v) Triton X-
100, 5% glycerol, 1 mg/ml lysozyme and 10 μg/ml DNase, and cells were lysed by sonication.
Cellular debris was pelleted by centrifugation and the soluble fraction was filtrated and loaded
into a 5 ml HisTrap HP column (GE Healthcare). The protein was eluted using an imidazole
gradient (10–500 mM) in 50 mM Tris pH 8.0 and 300 mMNaCl. Protein fractions were dia-
lyzed against 20 mM Tris pH 9.0, 600 mMNaCl, 15% glycerol, 0.5 mM TCEP and further puri-
fied by size-exclusion chromatography on a Superdex 200 16/60 column (GE Healthcare).
Purified protein was concentrated to 5 mg/ml in the same buffer, using a Vivaspin concentrator
(10.000 MWCO PES, Sartorius Stedim Biotech). The quality of the protein obtained was
checked by SDS-PAGE.
EMCV 3Dpol wt and mutants were expressed and purified as previously reported for EMCV
3Dpol wt [29]. Briefly, using the constructs described above, the polymerases were overex-
pressed in E. coli, and EMCV 3Dpol was purified by means of Ni-affinity (HisTrap HP, GE
Healthcare). After that, the His-tag was removed by TEV digestion, and size exclusion chroma-
tography (Superdex 200 16/60, GE Healthcare).
Crystallization and data collection
Crystals of isolated CVB3 3Dpol were obtained by the sitting-drop vapor-diffusion method
at 16°C in 96-well plates (MRC, Swissci AG) using a Cartesian automated drop dispenser to
mix 250 nl of 5 mg/ml protein solution with an equal volume of reservoir solution, containing
50 mM Tris pH 7.5, 24.5% (w/v) glycerol, 1.29 M ammonium sulfate. Highly reproducible crys-
tals of 25x25x25 μm in size appeared between 2–3 days. Protein/inhibitor complexes were pre-
pared by soaking CVB3 3Dpol crystals in the inhibitor solution for 72h. The inhibitor solutions
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contained 100 μMGPC-N114 or GPC-N143 in 2.5% DMSO, 0.65 M ammonium sulfate,
12.5% glycerol and 25 mM Tris pH 7.5. Crystals were then transferred to a cryo-protecting so-
lution, containing 30% glycerol in the respective crystallization buffer prior to cooling by im-
mersion in liquid nitrogen. The two datasets were collected at 100K by using synchrotron
radiation at the European Synchrotron Radiation Facility (ESRF, Grenoble) on a Pilatus 6M S/
N 60–104 detector at beamline ID 29, λ = 0.977Å. Diffraction images were processed with
iMOSFLM [52] and internally scaled with SCALA (CCP4i [53]), achieving resolutions of 2.9Å
and 2.7Å for the CVB3 3Dpol–GPC-N114 and CVB3 3Dpol–GPC-N143 crystals, respectively.
Data collection statistics are given in Table 2. Coordinates have been deposited at the PDB
with accession codes 4Y2A and 4Y34 for the complexes CVB3 3Dpol–GPC-N114 and CVB3
3Dpol–GPC-N143, respectively.
Crystals of EMCV 3Dpol wt and M300V and I304V, mutants were obtained as previously
described [29]. The data sets were collected at the ALBA-CELLS synchrotron light facility (Bar-
celona) on a Pilatus 6M Dectris detector at beamline XALOC λ = 0.977Å. Diffraction images
were processed with iMOSFLM and SCALA, achieving resolutions of 2.2Å and 3.2Å for the
M300V and I304V respectively (Table 2). Coordinates have been deposited at the PDB with ac-
cession codes 4Y2C and 4Y3C for the structures of EMCV 3Dpol-M300V and EMCV 3Dpol-
I304V, respectively.
Structure determination and refinement
The initial electron density maps of the CVB3 3Dpol–GPC-N114 and CVB3 3Dpol–GPC-N143
complexes were obtained after rigid-body fitting of the coordinates of the 3Dpol apoenzymes
(PDB id. 3DDK) to the new unit cells (Table 2), using the program Refmac5 [54,55]. In both
structures, the weighted 2|Fo|-|Fc| and |Fo|-|Fc| difference map showed the presence of extra
densities that permitted the initial positioning of the inhibitor molecules. Inhibitor structure
files were generated using “Online SMILES Translator and Structure File Generator” (http://
cactus.nci.nih.gov/translate/) and its respective CIF dictionaries were created by Grade [56].
Several cycles of automatic refinement, performed with Refmac5, were alternated with manual
model rebuilding using Coot [57]. The refinement statistics are summarized in Table 2.
The first electron density maps for both EMCV 3Dpol mutants were obtained after rigid-
body fitting of the EMCV 3Dpol wt coordinates to the new unit cells. The PDB id 4NYZ, of
space group I4122, was used as a model for the M300V structure and coordinates 4NZ0, of
space group C2, were used as a model for the I304V mutant. Noncrystallographic symmetry
(ncs) restraints were initially applied to the six independent molecules present in the asymmet-
ric unit of the C2 crystals using Refmac5. However, the ncs restrained-refinement result was
unstable because the presence of different conformations in many polymerase regions, espe-
cially in the surface-exposed loops, was affected by crystal packing interactions. Therefore, the
variable regions were manually rebuilt using Coot, and the final cycles of automatic refinement
with Refmac 5, were performed in absence of ncs restraints. The refinement statistics are given
in Table 2.
Supporting Information
S1 Fig. Effect of GPC-N114 on cell viability and picornavirus replication. (A) GPC-N114
does not affect cell viability. BGM cells were treated with GPC-N114 for 8 h after which cell vi-
ability was determined with an MTS assay. Cell viability is expressed as percentage of DMSO-
treated cells. Experiments were performed in triplicate and mean values ± SD are depicted. (B)
Antiviral activity of GPC-N114 against picornaviruses. BGM cells were infected with the indi-
cated viruses at an MOI of 0.5. GPC-N114 (10 μM) was added immediately after infection. At
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0, 8 and 24 h p.i. virus titers were determined by endpoint titration. Experiments were done in
triplicate and mean values ± SD are shown.
(TIF)
S2 Fig. GPC-N114 does not affect polyprotein processing. BGM cells were infected with
CVB3 at MOI 50. At 5 h p.i. cells were starved for methionine for 30 min after which produced
proteins were labeled with [35S]Met in the presence of DMSO or 50 μMGPC-N114 for another
30 min. Subsequently, proteins were analyzed by SDS-PAGE.
(TIF)
S3 Fig. Replication of PV1 is completely inhibited by GPC-N114. The experiment was per-
formed as described in Fig. 1F.
(TIF)
S4 Fig. Mutations I296V, M300V, and S299T in 3Dpol do not confer resistance to CVB3.
(A) BGM cells were infected with CVB3 wt or mutants at an MOI of 0.5 for 30 min. Subse-
quently, the inoculum was replaced with medium containing DMSO, GPC-N114, or guanidine
hydrochloride (GuHCl). Virus titers were determined by endpoint titration after 8 h. Experi-
ments were performed in triplicate and mean values ± SD are depicted. (B) Dose-response
curves of multicycle CPE-reduction assays with CVB3 wt and CVB3 3D-S299T on BGM cells.
CPE was quantified by MTS assay at 3 d p.i. and is expressed as percentage of uninfected,
untreated controls.
(TIF)
S5 Fig. GPC-N114 has no effect on DENV NS5 RdRP elongation activity. DENV NS5 RdRP
elongation activity in the presence of a range of concentrations of GPC-N114 was determined
by measuring incorporation of [3H]UTP using poly(rA)/dT15 as template-primer. The activity
observed with DMSO was set at 100%. Experiments were performed in triplicate and values
shown are mean ± SD.
(TIF)
S6 Fig. Stereoview of the Fo-Fc omit map (contoured at 3.0 σ) around the inhibitor pocket
for the CVB3 3Dpol–GPC-N114 complex. The polymerase residues in direct contact with the
inhibitor are shown with carbon atoms in green and explicitly labeled. Hydrogen bonds are de-
picted as dashed lines.
(TIF)
S7 Fig. Sequence alignment of picornavirus RdRPs. The strictly conserved residues are in red
blocks and similar residues in blue boxes. The residues interacting with GPC-N114 are marked
by green (CVB3) and blue squares (EMCV).
(TIF)
S8 Fig. GPC-N143. (A) Antiviral activity of GPC-N143 against CVB3 and EMCV. The ex-
periment was performed as in Fig. 1C. Experiments were performed in triplicate and mean
values ± SD are depicted. (B) GPC-N143 does not affect cell viability. The experiment was
performed as in S1A Fig. Experiments were performed in triplicate and mean values ± SD are
depicted. (C) Structural formula of GPC-N143. (D) Stereoview of the Fo-Fc omit map (con-
toured at 3.0 σ) around the inhibitor pocket for the CVB3 3Dpol–GPC-N143 complex. The in-
hibitor contacting residues in the polymerase binding pocket are indicated.
(TIF)
S9 Fig. Sym/sub-U assay. (A) The sequence of the sym/sub template primer duplex. (B-C)
GPC-N114 has no effect on NTP incorporation in the sym/sub-U assay. NTPs (500 μM) were
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incubated in a buffer containing 50 mM Tris pH 7.0, 10 mM KCl, and 0.8 mMMgCl2 for
5 min. GPC-N114 or DMSO were added and the mix was incubated for another minute, fol-
lowed by addition of 1 μMCVB3 3Dpol. After a two-minute incubation, the reaction was initi-
ated with [32P]-labeled sym/sub-u (1 μM) and quenched at 30, 60, 90, 120, 180 and 300s after
the initiation. Reaction products were analyzed by electrophoresis on a denaturing polyacryl-
amide gel (C). The quantification of the incorporation of NTPs is depicted in (B).
(TIF)
S10 Fig. Effect of Y195 on the binding of GPC-N114. Cartoon representation of the GPC-
N114-binding pocket in CVB3 3Dpol (forest green) (A) and the putative inhibitor pocket in
EMCV (slate blue) (B). Polymerase side chains are represented in sticks only for: i) Y195 in
CVB3 3Dpol, making crucial interactions with the compound, and its equivalent (A195) in
EMCV 3Dpol, ii) the EMCV residues M300 and I304 that are mutated in GPC-N114-resistant
mutants and the equivalent amino acids in CVB3 3Dpol (I296 and M300). The inhibitor is rep-
resented in atom-type sticks with carbon atoms in yellow.
(TIF)
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